Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase NA 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 12Other hematologic neoplasm 9Thoracic 8Lymphoid 6Gynecologic 5CNS 5Breast 4Tumor-Agnostic 3Sarcoma 2Plasma cell 2Head & Neck 2Genitourinary 2Dermatologic 2Myeloid 1Endocrine 1Classical hematology 1

Conditions

Smoldering Multiple Myeloma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1

Interventions

Dexamethasone 177Bortezomib 98Lenalidomide 90daratumumab 46Melphalan 45Thalidomide 44pomalidomide 42Cyclophosphamide 38Calcium Dobesilate 30carfilzomib 29Prednisone 19Doxorubicin 16elotuzumab 14Filgrastim 14ixazomib 11isatuximab 11Granulocyte Colony-Stimulating Factor 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10dexamethasone acetate 9belantamab mafodotin 9Zoledronic Acid 8selinexor 7Epoetin Alfa 7fludarabine 6Etoposide 6dexamethasone 21-phosphate 5auricularum 5Mycophenolic Acid 5Cisplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Observation × Plasma cell × Clear all
NCT01169337 2026-05-01

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
226 enrolled 16 charts
Plasma cell

Smoldering Multiple Myeloma

NCT00075829 2021-11-01

BMT CTN 0102

National Heart, Lung, and Blood Institute (NHLBI)

Phase 3 Completed
710 enrolled 19 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡